<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>935</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10727884</PubmedId>
            <Abstract>Outer membrane protein F of Pseudomonas aeruginosa has vaccine efficacy against infection by P. aeruginosa as demonstrated in a variety of animal models. Through the use of synthetic peptides, three surface-exposed epitopes have been identified. These are called peptides 9 (aa 261-274 in the mature F protein, TDAYNQKLSERRAN), 10 (aa 305-318, NATAEGRAINRRVE), and 18 (aa 282-295, NEYGVEGGRVNAVG). Both the peptide 9 and 10 epitopes are protective when administered as a vaccine. In order to develop a vaccine that is suitable for use in humans, including infants with cystic fibrosis, the use of viral vector systems to present the protective epitopes has been investigated. An 11-amino acid portion of epitope 10 (AEGRAINRRVE) was successfully inserted into the antigenic B site of the hemagglutinin on the surface of influenza virus. This chimeric influenza virus protects against challenge with P. aeruginosa in the mouse model of chronic pulmonary infection. Attempts to derive a chimeric influenza virus carrying epitope 9 have been unsuccessful. A chimeric plant virus, cowpea mosaic virus (CPMV), with epitopes 18 and 10 expressed in tandem on the large coat protein subunit (CPMV-PAE5) was found to elicit antibodies that reacted exclusively with the 10 epitope and not with epitope 18. Use of this chimeric virus as a vaccine afforded protection against challenge with P. aeruginosa in the mouse model of chronic pulmonary infection. Chimeric CPMVs with a single peptide containing epitopes 9 and 18 expressed on either of the coat proteins are in the process of being evaluated. Epitope 9 was successfully expressed on the coat protein of tobacco mosaic virus (TMV), and this chimeric virus is protective when used as a vaccine in the mouse model of chronic pulmonary infection. However, initial attempts to express epitope 10 on the coat protein of TMV have been unsuccessful. Efforts are continuing to construct chimeric viruses that express both the 9 and 10 epitopes in the same virus vector system. Ideally, the use of a vaccine containing two epitopes of protein F is desirable in order to greatly reduce the likelihood of selecting a variant of P. aeruginosa that escapes protective antibodies in immunized humans via a mutation in a single epitope within protein F. When the chimeric influenza virus containing epitope 10 and the chimeric TMV containing epitope 9 were given together as a combined vaccine, the immunized mice produced antibodies directed toward both epitopes 9 and 10. The combined vaccine afforded protection against challenge with P. aeruginosa in the chronic pulmonary infection model at approximately the same level of efficacy as provided by the individual chimeric virus vaccines. These results prove in principle that a combined chimeric viral vaccine presenting both epitopes 9 and 10 of protein F has vaccine potential warranting continued development into a vaccine for use in humans.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>291-7</ArticlePages>
            <ArticleTitle>Chimeric animal and plant viruses expressing epitopes of outer membrane protein F as a combined vaccine against Pseudomonas aeruginosa lung infection.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Gilleland</LastName>
                    <ForeName>H E</ForeName>
                </Author>
                <Author>
                    <LastName>Gilleland</LastName>
                    <ForeName>L B</ForeName>
                </Author>
                <Author>
                    <LastName>Staczek</LastName>
                    <ForeName>J</ForeName>
                </Author>
                <Author>
                    <LastName>Harty</LastName>
                    <ForeName>R N</ForeName>
                </Author>
                <Author>
                    <LastName>Garc√≠a-Sastre</LastName>
                    <ForeName>A</ForeName>
                </Author>
                <Author>
                    <LastName>Palese</LastName>
                    <ForeName>P</ForeName>
                </Author>
                <Author>
                    <LastName>Brennan</LastName>
                    <ForeName>F R</ForeName>
                </Author>
                <Author>
                    <LastName>Hamilton</LastName>
                    <ForeName>W D</ForeName>
                </Author>
                <Author>
                    <LastName>Bendahmane</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Beachy</LastName>
                    <ForeName>R N</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Microbiology and Immunology, Louisiana State University Medical Center, School of Medicine in Shreveport, Shreveport, LA 71130-3932, USA. hgille@lsumc.edu.</Affiliations>
            <ArticleChemicalList>Antibodies, Bacterial;Bacterial Vaccines;Epitopes;Porins;Recombinant Fusion Proteins;Vaccines, Combined;Vaccines, Synthetic</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Bacterial(blood); Bacterial Vaccines(administration &amp; dosage; immunology); Comovirus(genetics; metabolism); Enzyme-Linked Immunosorbent Assay; Epitopes(genetics; immunology; metabolism); Influenza A virus(genetics; metabolism); Lung(microbiology); Lung Diseases(microbiology; prevention &amp; control); Mice; Plant Viruses(genetics; metabolism); Porins(chemistry; immunology; metabolism); Pseudomonas Infections(prevention &amp; control); Pseudomonas aeruginosa(immunology); Recombinant Fusion Proteins(genetics; immunology; metabolism); Tobacco Mosaic Virus(genetics; metabolism); Vaccination; Vaccines, Combined(administration &amp; dosage; immunology); Vaccines, Synthetic(administration &amp; dosage; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>27</Volume>
                <Issue>4</Issue>
                <Title>FEMS immunology and medical microbiology</Title>
                <Issn>1574-695X</Issn>
                <MedlineTa>FEMS Immunol Med Microbiol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Peptide 9</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TDAYNQKLSERRAN</LinearSequence>
                        <StartingPosition>285</StartingPosition>
                        <EndingPosition>298</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13794.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000723</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 292</LocationOfData>
                <EpitopeId>63122</EpitopeId>
                <ReferenceStartingPosition>261</ReferenceStartingPosition>
                <ReferenceEndingPosition>274</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Peptide shown to provide protection to source species challenge in a mouse model of chronic pulmonary infection. No increase in protective efficacy was seen for the combined administration of another epitope (peptide 10) from source species. Swiss-Prot entry corresponds to the precursor protein while the positions given in the manuscript correspond to the mature form. This protein is antigenically conserved in all strains of source species.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Tables 4 and 5</LocationOfData>
                        <BCellId>10841</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000618</OrganismId>
                                <Age>5 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TDAYNQKLSERRAN</LinearSequence>
                                            <StartingPosition>285</StartingPosition>
                                            <EndingPosition>298</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P13794.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000723</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Peptide 9</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>12242</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>3 immunizations 2 weeks apart. 1st: 50 micrograms of virions, 2nd: 10 micrograms, 3rd: 10 micrograms without adjuvant.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>2 weeks after final immunization, mice were infected with source species intratracheally (~5x10^3 pfu). 8 days later, pulmonary infection status was assessed analyzing number and size of lesions and number of source species cells present.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>125</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>28</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>16</NumberOfSubjectsResponded>
                            <ResponseFrequency>57.1</ResponseFrequency>
                            <AssayComments>16 out of 28 mice immunized with recombinant tobacco mosaic virus (TMV) expressing epitope inserted in coat protein are shown to have normal (without lesions) lungs upon source species challenge, while 6 out of 30 mice have normal lungs in wild type TMV immunized mice. In mice infected with a mixture of this virus and a recombinant Influenza virus expressing peptide 10 from the source protein, similar results are obtained, with 15 out of 28 mice having normal lungs. Absence of source species in lung tissue correlates with the lack of lesions.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Pseudomonas aeruginosa</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000723</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <BCellId>10840</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000618</OrganismId>
                                <Age>5 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TDAYNQKLSERRAN</LinearSequence>
                                            <StartingPosition>285</StartingPosition>
                                            <EndingPosition>298</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P13794.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000723</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Peptide 9</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>12242</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>3 immunizations 2 weeks apart. 1st: 50 micrograms of virions, 2nd: 10 micrograms, 3rd: 10 micrograms without adjuvant.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>2 weeks after final immunization, 5 mice were sacrificed and sera was pooled for analysis of ELISA reactivity against epitope and source species.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Pooled serum from 5 mice immunized with recombinant tobacco mosaic virus (TMV) expressing epitope inserted in coat protein are shown to have high titers (&gt;6400) of antibodies directed against the epitope and the source species, but not source species mutant lacking F protein. In mice infected with a mixture of this virus and a recombinant Influenza virus expressing peptide 10 from source protein, similar results are obtained. No reactivity is seen with the wild type carrier virus.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Peptide 9</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TDAYNQKLSERRAN</LinearSequence>
                                        <StartingPosition>285</StartingPosition>
                                        <EndingPosition>298</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P13794.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000723</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 10</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NATAEGRAINRRVE</LinearSequence>
                        <StartingPosition>329</StartingPosition>
                        <EndingPosition>342</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P13794.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000723</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 292</LocationOfData>
                <EpitopeId>43317</EpitopeId>
                <ReferenceStartingPosition>305</ReferenceStartingPosition>
                <ReferenceEndingPosition>318</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Peptide shown to provide protection to source species challenge in a mouse model of chronic pulmonary infection.  No increase in protective efficacy was seen for the combined administration of another epitope (peptide 9) from source species. Swiss-Prot entry corresponds to the precursor protein while the positions given in the manuscript correspond to the mature form. This protein is antigenically conserved in all strains of source species.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <BCellId>10853</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000618</OrganismId>
                                <Age>5 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>NATAEGRAINRRVE</LinearSequence>
                                            <StartingPosition>329</StartingPosition>
                                            <EndingPosition>342</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P13794.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000723</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Peptide 10</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>3 immunizations 2 weeks apart. 1st intranasal with 10&lt;sup&gt;3&lt;/sup&gt; pfu, 2nd intramuscular (10&lt;sup&gt;5&lt;/sup&gt; pfu) with alum, and 3rd Intramuscular without alum (10&lt;sup&gt;5&lt;/sup&gt; pfu).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>2 weeks after final immunization, 5 mice were sacrificed and sera was pooled for analysis of ELISA reactivity against epitope and source species. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Pooled serum from 5 mice immunized with recombinant influenza virus expressing epitope inserted in hemagglutinin protein are shown to have antibodies directed against  the epitope and the source species, but not to source species mutant lacking F protein. In mice infected with a mixture of this virus and a recombinant  tobacco mosaic virus (TMV) expressing peptide 9 from the source protein, results are similar but higher titers are obtained. No reactivity is seen with the wild type carrier virus.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Peptide 10</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NATAEGRAINRRVE</LinearSequence>
                                        <StartingPosition>329</StartingPosition>
                                        <EndingPosition>342</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P13794.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000723</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Tables 4 and 5</LocationOfData>
                        <BCellId>10855</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000618</OrganismId>
                                <Age>5 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>NATAEGRAINRRVE</LinearSequence>
                                            <StartingPosition>329</StartingPosition>
                                            <EndingPosition>342</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P13794.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10000723</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Peptide 10</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Intranasal</Route>
                                <DoseSchedule>3 immunizations 2 weeks apart. 1st intranasal with 10&lt;sup&gt;3&lt;/sup&gt; pfu, 2nd intramuscular (10&lt;sup&gt;5&lt;/sup&gt; pfu) with alum, and 3rd Intramuscular without alum (10&lt;sup&gt;5&lt;/sup&gt; pfu).</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>2 weeks after final immunization, mice were infected with source species intratracheally (~5x10&lt;sup&gt;3&lt;/sup&gt; pfu). 8 days later, pulmonary infection status was assessed analyzing number and size of lesions and number of source species cells present. .</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>125</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>29</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>20</NumberOfSubjectsResponded>
                            <ResponseFrequency>69</ResponseFrequency>
                            <AssayComments>20 out of 29 mice immunized with recombinantinfluenza virus expressing epitope inserted in hemmaglutinin protein are shown to have normal (without lesions) lungs upon source species challenge, while 7 out of 29 mice with normal lungs were seen in wild type TMV immunized mice. In mice infected with a mixture of this virus and a recombinant tobacco mosaic virus expressing peptide 9 from source protein, similar results are obtained, with 15 out of 28 mice having normal lungs. Absence of source species in lung tissue correlates with the lack of lesions.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenReferenceName>Pseudomonas aeruginosa</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>10000723</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

